Report ID: SQSG35I2036
Report ID:
SQSG35I2036 |
Region:
Global |
Published Date: April, 2024
Pages:
157
|
Tables:
63 |
Figures:
75
North America dominated the global duchenne muscular dystrophy market. The market in North America is expected to expand as a result of a number of important factors, including the rising prevalence of muscular dystrophy in the region, FDA drug approval, strong healthcare infrastructure supported by supportive government regulations, and medical reimbursement in the region and due to anticipated product launches.
Asia Pacific market is expected to hold the second largest share of global market. On the back of the region's high prevalence of musculoskeletal illnesses and large male population. In India, for example, 51.96% of the population would be male, according to the World Bank. In addition, it is expected that the market will rise due to the ongoing improvement of public healthcare services and strong economic expansion. The pharmaceutical firms in the region are relocating clinical trial operations to new trial areas, which are primarily low- and middle-income countries. Additionally, the region's high frequency of the target condition is anticipated to fuel regional market expansion.
Our industry expert will work with you to provide you with customized data in a short amount of time.
REQUEST FREE CUSTOMIZATIONWant to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.
Report ID: SQSG35I2036